Abstract
Anxiety disorders, such as post-traumatic stress (PTSD), panic, and phobic disorders, can be conceptualized as a failure to inhibit inappropriate fear responses. A common, effective treatment strategy involves repeated presentations to the feared cue without any danger (extinction). However, extinction learning has a number of important limitations, and enhancing its effects, generalizability and durability via cognitive enhancers may improve its therapeutic impact. In this review we focus specifically on the role of the cannabinoid system in fear extinction learning and its retention. We address the following questions: What are the neural circuits mediating fear extinction?; Can we make fear extinction more effective?; Can cannabinoids facilitate fear extinction in humans?; How might the cannabinoid system effect fear extinction? Collectively, translational evidence suggest that enhancing cannabinoid transmission may facilitate extinction learning and its recall, and that the cannabinoid system is a potential pharmacological target for improving the active learning that occurs during exposure-based behavioral treatments prompting future research in terms of mechanisms research, novel treatment approaches (‘cognitive enhancers’), and pharmacotherapeutic drug discovery.
Keywords: Cannabinoid, fear extinction, cognitive enhancer, ventromedial prefrontal cortex, hippocampus, amygdala, anxiety.
Current Pharmaceutical Design
Title:Cannabinoid Modulation of Fear Extinction Brain Circuits: A Novel Target to Advance Anxiety Treatment
Volume: 20 Issue: 13
Author(s): Christine A. Rabinak and K. Luan Phan
Affiliation:
Keywords: Cannabinoid, fear extinction, cognitive enhancer, ventromedial prefrontal cortex, hippocampus, amygdala, anxiety.
Abstract: Anxiety disorders, such as post-traumatic stress (PTSD), panic, and phobic disorders, can be conceptualized as a failure to inhibit inappropriate fear responses. A common, effective treatment strategy involves repeated presentations to the feared cue without any danger (extinction). However, extinction learning has a number of important limitations, and enhancing its effects, generalizability and durability via cognitive enhancers may improve its therapeutic impact. In this review we focus specifically on the role of the cannabinoid system in fear extinction learning and its retention. We address the following questions: What are the neural circuits mediating fear extinction?; Can we make fear extinction more effective?; Can cannabinoids facilitate fear extinction in humans?; How might the cannabinoid system effect fear extinction? Collectively, translational evidence suggest that enhancing cannabinoid transmission may facilitate extinction learning and its recall, and that the cannabinoid system is a potential pharmacological target for improving the active learning that occurs during exposure-based behavioral treatments prompting future research in terms of mechanisms research, novel treatment approaches (‘cognitive enhancers’), and pharmacotherapeutic drug discovery.
Export Options
About this article
Cite this article as:
Rabinak A. Christine and Phan Luan K., Cannabinoid Modulation of Fear Extinction Brain Circuits: A Novel Target to Advance Anxiety Treatment, Current Pharmaceutical Design 2014; 20 (13) . https://dx.doi.org/10.2174/13816128113199990437
DOI https://dx.doi.org/10.2174/13816128113199990437 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews Commentary Research Highlights (Purines, Pores and Pain: Is it in Our Genes?)
CNS & Neurological Disorders - Drug Targets Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine Neuroprotective Properties of Curcumin in Alzheimer’s Disease – Merits and Limitations
Current Medicinal Chemistry Editorial [Hot topic: NKT Cell Therapy (Guest Editor: Masashi Emoto)]
Current Immunology Reviews (Discontinued) Brain Inflammation Following Intracerebral Hemorrhage
Current Neuropharmacology Disulfiram: An Old Therapeutic with New Applications
CNS & Neurological Disorders - Drug Targets Evaluation of Self Monitoring of Blood Glucose in Non-Insulin-Treated Diabetic Patients by Randomized Controlled Trials: Little Bang for the Buck
Reviews on Recent Clinical Trials Advances in Spirocyclic Hybrids: Chemistry and Medicinal Actions
Current Medicinal Chemistry In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Pharmacotherapy for Late-Life Depression with Psychotic Features: A Review of Literature of Randomized Control Trials
Current Psychiatry Reviews Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Promotion of Remyelination by Immunoglobulins: Implications for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Pediatric Speech Perception in Noise
Current Pediatric Reviews Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?
Current Neuropharmacology Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Selective α7 Nicotinic Acetylcholine Receptor Ligands
Current Medicinal Chemistry How Much Vitamin D is Too Much? A Case Report and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer Chemopreventive Agents Discovered by Activity-Guided Fractionation: An Update
Current Organic Chemistry